Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering

• Erasca Inc (NASDAQ: ERAS) has entered into an exclusive worldwide license agreement with Novartis AG (NYSE: NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor for NRAS mutant (NRASm) melanoma and other RAS/MAPK pathway-driven tumors.

• To date, naporafenib has been dosed in over 500 patients across multiple trials and has demonstrated preliminary clinical proof-of-concept and favorable safety and tolerability, Erasca says.

• Erasca will pay Novartis a one-time upfront cash payment of $20 million and $80 million in Erasca shares at $6.50 per share.

• Novartis is eligible to receive up to $80 million in cash upon achieving regulatory milestones covering two indications in the U.S., Europe, and Japan and up to $200 million in cash upon achieving sales milestones.

• Novartis is also eligible to receive a low single-digit percentage royalty on net sales of naporafenib.

• As separately announced, Erasca has priced a $100 million equity offering with 15.38 million shares at $6.50/share.

• Price Action: ERAS shares are down 13.2% at $6.34 on the last check Friday.

See more from Benzinga

• Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate

• Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From Breast Cancer Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.